Group 1 - The core point of the article is that CITIC Securities has been entrusted by shareholders of VeriSilicon Limited to organize a price inquiry for the transfer of shares before the initial public offering of VeriSilicon [1][2] - The inquiry transfer is conducted in accordance with relevant regulations, including the implementation opinions on the establishment of the Sci-Tech Innovation Board and pilot registration system [1][2] - CITIC Securities has completed the qualification verification of the transferring shareholders and has issued a verification opinion [1][16] Group 2 - The verification process included interviews and inquiries with the transferring shareholders, as well as the collection of relevant verification documents [2][16] - VeriSilicon Limited, the largest shareholder of VeriSilicon, is a foreign entity established on June 16, 2016, and is legally existing without any termination circumstances [2][3] - The transferring shareholders have not violated any regulations regarding share reduction or their commitments [3][5] Group 3 - The shares to be transferred are pre-IPO shares and are not subject to any pledges or judicial freezes [5][10] - The transferring shareholders have fulfilled necessary review or approval procedures for the transfer [5][10] - The inquiry transfer must comply with the guidelines regarding the window period for share reduction, ensuring that no major events affecting stock prices occur during this period [15][16]

中信证券股份有限公司 关于 上海证券交易所 《关于淮河能源（集团）股份有限公司发行股份 及支付现金购买资产暨关联交易申请的审核问询 函》 之回复报告 之专项核查意见 独立财务顾问 二〇二五年八月 上海证券交易所： 淮河能源（集团）股份有限公司（以下简称"淮河能源"、"上市公司"或 "公司"）于 2025 年 6 月 6 日收到贵所下发的《关于淮河能源（集团）股份有 限公司发行股份及支付现金购买资产暨关联交易申请的审核问询函》（上证上审 （并购重组）[2025]37 号，以下简称"《问询函》"）。中信证券股份有限公司 （以下简称"中信证券"或"独立财务顾问"）作为淮河能源的独立财务顾问， 会同上市公司及其他中介机构根据问询函的相关要求，就问询函所列问题进行 了认真核查和逐项落实，现就问询函相关内容作如下回复说明，并根据问询函 对有关问题进行了进一步说明和披露。 如无特殊说明，本回复中出现的简称均与《重组报告书》中的释义内容相 同。 | 审核问询函所列问题 | 黑体 | | --- | --- | | 审核问询函所列问题的回复 | 宋体 | | 对《重组报告书》的引用 | 宋体 | 本文涉及数字均按照四舍五入保留 ...

Core Viewpoint - The first batch of Sci-Tech Innovation Bond ETFs has seen significant growth, with a total scale exceeding 110 billion yuan, indicating strong market interest and investment value in this sector [1][5][10]. Group 1: ETF Expansion and Market Dynamics - The second batch of Sci-Tech Innovation Bond ETFs has been officially submitted, with 14 fund companies participating, indicating a growing interest in this investment vehicle [3][4]. - The first batch of 10 ETFs sold out on the first day, with a total fundraising amount of 28.988 billion yuan, and the overall scale has increased to 117.95 billion yuan, representing a growth of approximately 307% [5][10]. - The trading turnover rate of Sci-Tech Innovation Bonds increased from below 10% to 18% in the first month after the first batch was launched, reflecting improved liquidity [1][10]. Group 2: Investment Value and Market Outlook - The market for Sci-Tech Innovation Bonds has rapidly expanded, with a total market size of approximately 2 trillion yuan, driven by policy support and increasing issuance [8][9]. - Analysts predict that the issuance of Sci-Tech Innovation Bonds will play a crucial role in the transformation of economic drivers, shifting focus from traditional industries to technology innovation [9][11]. - The performance of the Sci-Tech Innovation Bond indices has outperformed traditional long-term bond indices, with annualized returns of around 4.6% compared to 3.2% for long-term pure bond fund indices [10]. Group 3: Institutional Participation and Strategic Importance - Major fund companies view the Sci-Tech Innovation Bond ETFs as a strategic tool to enhance their fixed-income product lines and provide investors with access to technology sector growth [6][11]. - The involvement of custodial institutions, such as Industrial Bank and China Merchants Bank, highlights the competitive landscape and institutional interest in these ETFs [5]. - The ETFs are expected to facilitate the flow of financial resources into the technology sector, supporting innovation and economic development [6][11].

Core Viewpoint - JinkoSolar Technology Co., Ltd. has completed the project "Baotou Jinko (Phase III) 20GW Pulling and Slicing Project" and has decided to conclude this fundraising project as it has reached the intended usable state [1][4]. Fundraising Overview - The company issued 89,603,077 convertible bonds with a face value of RMB 100 each, raising a total of RMB 8,960,307,700, with a net amount of RMB 8,933,848,025.97 after deducting issuance costs [1][2]. - The funds raised will be allocated to several projects, including: - Baotou Jinko (Phase III) 20GW Pulling and Slicing Project: RMB 2,700,000,000 - Annual production of 10GW high-efficiency batteries and 5GW high-efficiency modules: RMB 2,334,484,600 - Annual production of 10GW high-efficiency solar cells: RMB 1,500,000,000 - Supplementing working capital: RMB 2,399,363,425.97 - Total: RMB 8,933,848,025.97 [2]. Project Implementation and Conclusion - The "Baotou Jinko (Phase III) 20GW Pulling and Slicing Project" has been audited and confirmed to have reached the intended usable state, with the following financial details: - Total investment: RMB 305,755.16 million - Net interest income: RMB 305,736.55 million - Remaining funds: RMB 0.00 million [4][6]. - The project has no surplus funds, and any excess investment beyond the planned amount will be covered by the company's own funds [5]. Regulatory Compliance and Approval - The conclusion of the fundraising project was approved by the company's sixth board of directors and the supervisory board, confirming compliance with relevant regulations [7][8]. - The sponsor, CITIC Securities, has verified that the necessary approval procedures were followed and has no objections to the conclusion of the fundraising project [8].

Group 1 - Morgan Stanley is optimistic about the Chinese stock market's performance through the summer, citing improved liquidity and investor confidence in policy easing as key drivers [1] - The bank recommends an overweight position in A-shares compared to offshore Chinese stocks [1] - Onshore bond yields indicate a more positive long-term macro outlook among domestic investors [1] Group 2 - Deutsche Bank suggests that Fed Chair Powell is unlikely to signal a policy shift at the Jackson Hole symposium but may pave the way for a 25 basis point rate cut in September [2] - The bank expects Powell's statements to remain cautious, with no significant changes in guidance [2] Group 3 - CBA economists believe Powell's speech at Jackson Hole will influence the dollar's trajectory, but no clear signals are expected [3] - The probability of a rate cut in September is currently around 70%, setting a high bar for Powell to deviate from market expectations [3] Group 4 - CITIC Securities forecasts that 4.5 to 9 trillion yuan may flow into "fixed income plus" products as deposits mature, indicating a trend towards indirect market entry [4] - The firm anticipates over 90 trillion yuan in deposits maturing by 2025, with 5-10% potentially seeking higher returns [4] Group 5 - CITIC JianTou reports signs of a strong consumption season, with rising demand in energy and metals, leading to price increases in rare earths and lithium [5] - The firm notes that the upcoming consumption peak is expected to support prices in these sectors [5] Group 6 - Huatai Securities highlights increased trading activity and new account openings, indicating a recovery opportunity for brokers focused on wealth management transformation [6] - The A-share broker index is currently at a PBLF of 1.67x, suggesting potential for value re-evaluation [6] Group 7 - CITIC JianTou indicates an improvement in fiscal revenue for July, with a 0.1% year-on-year increase in general public budget revenue from January to July [7] - The report notes a positive trend in tax revenue, particularly from personal income and stamp taxes, reflecting marginal economic improvement [7] Group 8 - CITIC Securities anticipates over 5 trillion yuan may flow from deposits into "fixed income plus" products, driven by declining deposit yields and capital market performance [8] - The report suggests that insurance and wealth management products are increasingly prioritizing equity assets [8] Group 9 -招商策略 maintains an optimistic outlook on the Hong Kong stock market, suggesting a focus on innovative pharmaceuticals, followed by internet and new consumption sectors for investment [9] - The report notes that Hong Kong's earnings are improving, with a high earnings forecast rate, indicating a potential lead over A-shares [9]

中信证券股份有限公司 关于广东丸美生物技术股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"）作为广东丸美生物技术股 份有限公司（以下简称"丸美生物"或"公司"）首次公开发行股票的保荐人， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》 《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，对丸美生物使用部分闲置募集资金进行现金管理事项进行了审 慎核查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》 （证监许可[2019]917 号）核准，并经上海证券交易所同意， 丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为每股 人民币 20.54 元。共计募集资金人民币 84,214.00 万元，扣除各项发行费用人民 币 5,213.80 万元后的募集资金净额为人民币 79,000.20 万元。上述募集资金到位 情 ...

Group 1 - The core viewpoint of the article is that Yifang Biotechnology (Shanghai) Co., Ltd. plans to utilize part of its idle raised funds for cash management to enhance fund efficiency and returns for the company and its shareholders [1][2][5] Group 2 - The total amount of raised funds is RMB 208,380 million, with an issuance price of RMB 18.12 per share, approved by the China Securities Regulatory Commission on April 1, 2022 [1] - The company intends to use up to RMB 1 billion of temporarily idle raised funds for cash management, with a validity period of 12 months from the approval date by the board of directors [2] - The investment products will include low-risk, high-liquidity financial products such as structured deposits, time deposits, and large certificates of deposit, with a maximum investment period of 12 months [2] Group 3 - The decision to use idle funds for cash management was approved in the fifth meeting of the second board of directors on August 21, 2025, ensuring that it will not affect the normal operation of the company's main business or the progress of investment projects [2][4] - The company has established a robust approval and execution process for purchasing cash management products to ensure fund safety, including the use of dedicated settlement accounts [3][4] Group 4 - The sponsor, CITIC Securities, has verified that the company has followed necessary decision-making procedures and complies with relevant laws and regulations regarding the use of idle raised funds for cash management [5][6]

Summary of Key Points Core Viewpoint - The company, Yifang Biotechnology (Shanghai) Co., Ltd., is changing part of its fundraising investment projects to enhance the efficiency of its key research projects and the use of raised funds, specifically increasing the investment in the "New Drug Research and Development Project" [1][2]. Group 1: Fundraising and Investment Changes - The company raised a total of RMB 2,083.8 million through its initial public offering, with a net amount of RMB 1,982.15 million after deducting issuance costs [1]. - The board approved an increase in the total investment for the "New Drug Research and Development Project" from RMB 1,809.62 million to RMB 1,878.12 million, utilizing RMB 68.50 million of previously unallocated funds [2][10]. - The total planned investment for the headquarters construction project remains unchanged at RMB 1,982.15 million [2]. Group 2: Project Details and Rationale - The increase in funding for the D-2570 project, a TYK2 inhibitor for treating psoriasis and other autoimmune diseases, is necessary due to positive Phase II clinical trial results and the need for further clinical exploration [8][9]. - The company plans to allocate RMB 68.50 million for the Phase III clinical trial of D-2570 and its expansion into other indications, such as ulcerative colitis and systemic lupus erythematosus [8][9]. - The market for psoriasis treatment is significant, with approximately 12.5 million patients globally, indicating a strong demand for effective therapies [9]. Group 3: Approval and Compliance - The changes to the fundraising investment projects have been reviewed and approved by the company's board and will be submitted for shareholder approval [11]. - The company is committed to managing and utilizing the raised funds in accordance with relevant regulations and will ensure timely disclosure of project progress to protect investor interests [10][11].

对公司治理及持续经营产生重大影响； 股，剔除公司回购专户持股数后总股本为 1,365,879,984 股。 证券代码：001330 证券简称：博纳影业 公告编号：2025-041 号 博纳影业集团股份有限公司 关于股东减持变动触及 5%整数倍暨披露简式权益变动书的 提示性公告 股东中信证券投资有限公司及其一致行动人金石智娱股权投资(杭州)合伙企业(有限合 伙)、信石元影(深圳)投资中心(有限合伙)、青岛金石暴风投资咨询有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。本公司及董事会 全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 证投"）及其一致行动人金石智娱股权投资(杭州)合伙企业(有限合伙)（以下简称"金 石智娱"）、信石元影(深圳)投资中心(有限合伙) （以下简称"信石元影"）、青岛 金石暴风投资咨询有限公司（以下简称"青岛金石"）减持，不触及要约收购。 至 137,451,832 股，占公司总股本比例为 10.0000%（占剔除公司回购专户持股数后 总股本比例 10.0632%） （注：以上总数与各分项数值之和尾数不符的情况，均为四舍五入原因造 ...

中信证券股份有限公司关于天津创业环保集团股份有限公司 部分募投项目终止及部分募投项目延期的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为天津创业 环保集团股份有限公司（以下简称"创业环保"或"公司"）2021 年非公开发行股票 持续督导阶段的保荐人，根据《证券发行上市保荐业务管理办法》、 《上市公司募 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 集资金监管规则》 等相关法律、法规的规定，对创业环保本次部分募投项目终止及部分募投项目延 期的事项进行了审慎核查，核查情况及意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会于 2022 年 5 月 30 日签发的证监发行字 [2022]1122 号文《关于核准天津创业环保集团股份有限公司非公开发行股票的批 复》，公司于 2022 年 9 月向特定投资者非公开发行人民币普通股 143,189,655.00 股，每股发行价格为人民币 5.80 元，募集资金总额为 830,499,999.00 元，扣除发 行费用人民币 19,743,434.08 元后，募集资金净额共计人民币 810,756,564.92 元（以 下简 ...